


Accepted Manuscript

Clarification needed regarding anti-topoisomerase I as a biomarker for non-small cell lung cancer (Reply)

Xiao-hue Jiang, PhD, Shang-main Yie, PhD



PII: S0003-4975(18)30724-0

DOI: [10.1016/j.athoracsur.2018.04.078](https://doi.org/10.1016/j.athoracsur.2018.04.078)

Reference: ATS 31644

To appear in: *The Annals of Thoracic Surgery*

Received Date: 20 April 2018

Accepted Date: 26 April 2018

Please cite this article as: Jiang Xh, Yie Sm, Clarification needed regarding anti-topoisomerase I as a biomarker for non-small cell lung cancer (Reply), *The Annals of Thoracic Surgery* (2018), doi: 10.1016/j.athoracsur.2018.04.078.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Clarification needed regarding anti-topoisomerase I as a biomarker for non-small cell lung cancer (Reply)

Reply to the Editor:

We thank Drs Chan and Andrade for their comments [1] on our article [2]. Patients with systemic sclerosis (SSC), as a summary by Zeineddine *et al*, had a high risk of developing lung cancer when compared to the general population [3]. However, anti-SCL-70 autoantibodies, a hallmark of SSC, were not associated with the occurrence of various types of cancer including non-small cell lung cancer (NSCLC) [4].

In our recent report to the *Ann Thorac Surg*, none of the 127 NSCLC patients had SSC, and we actually measured a specific autoantibody against a novel tumor-associated antigen (TAA) rather than the anti-SCL-70 autoantibodies [2].

We have thoroughly illustrated the novel TAA and its specific autoantibody in a study published in the *British Journal of Cancer* [5]. The novel TAA with a molecular weight around 48 KD was identified as a fragment derived from human DNA topoisomerase I (TOP I), which corresponded to the 329–765 amino acid sequence of the protein. We also found that the novel TAA could induce its specific autoantibody with a high prevalence in some of the most common types of cancer including NSCLC.

Although the anti-SCL-70 autoantibodies could partially cross-react with the novel TAA, it is definitely distinct from the autoantibody against the novel TAA. This is because the immune reactions of the anti-SCL-70 autoantibodies from SSC

Download English Version:

<https://daneshyari.com/en/article/8951106>

Download Persian Version:

<https://daneshyari.com/article/8951106>

[Daneshyari.com](https://daneshyari.com)